A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis by Granville, Courtney A. et al.
A Central Role for Foxp3+ Regulatory T Cells in K-Ras-
Driven Lung Tumorigenesis
Courtney A. Granville
1., Regan M. Memmott
1., Andria Balogh
1, Jacopo Mariotti
2, Shigeru Kawabata
1,
Wei Han
1, Jaclyn LoPiccolo
1, Jason Foley
2, David J. Liewehr
3, Seth M. Steinberg
3, Daniel H. Fowler
2,M .
Christine Hollander
1, Phillip A. Dennis
1*
1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America, 2Experimental Transplantation and
Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America, 3Biostatistics and Data Management Section,
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
Abstract
Background: K-Ras mutations are characteristic of human lung adenocarcinomas and occur almost exclusively in smokers.
In preclinical models, K-Ras mutations are necessary for tobacco carcinogen-driven lung tumorigenesis and are sufficient to
cause lung adenocarcinomas in transgenic mice. Because these mutations confer resistance to commonly used cytotoxic
chemotherapies and targeted agents, effective therapies that target K-Ras are needed. Inhibitors of mTOR such as
rapamycin can prevent K-Ras-driven lung tumorigenesis and alter the proportion of cytotoxic and Foxp3+ regulatory T cells,
suggesting that lung-associated T cells might be important for tumorigenesis.
Methods: Lung tumorigenesis was studied in three murine models that depend on mutant K-Ras; a tobacco carcinogen-
driven model, a syngeneic inoculation model, and a transgenic model. Splenic and lung-associated T cells were studied
using flow cytometry and immunohistochemistry. Foxp3+ cells were depleted using rapamycin, an antibody, or genetic
ablation.
Results: Exposure of A/J mice to a tobacco carcinogen tripled lung-associated Foxp3+ cells prior to tumor development. At
clinically relevant concentrations, rapamycin prevented this induction and reduced lung tumors by 90%. In A/J mice
inoculated with lung adenocarcinoma cells resistant to rapamycin, antibody-mediated depletion of Foxp3+ cells reduced
lung tumorigenesis by 80%. Likewise, mutant K-Ras transgenic mice lacking Foxp3+ cells developed 75% fewer lung tumors
than littermates with Foxp3+ cells.
Conclusions: Foxp3+ regulatory T cells are required for K-Ras-mediated lung tumorigenesis in mice. These studies support
clinical testing of rapamycin or other agents that target Treg in K-Ras driven human lung cancer.
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Introduction
Lung cancer has been the leading cause of cancer deaths in
American men since 1954 and in American women since 1987 [1],
which reflects historical differences in smoking habits. Lung cancer
remains a daunting problem that is mostly related to smoking, with
over 215,000 new cases and 160,000 deaths expected in the US in
2008 [1]. Smoking is associated with resistance to cytotoxic
chemotherapies and targeted therapies in lung cancer patients,
and over 90 million current or former smokers in the United States
are at permanent increased risk to develop lung cancer [2]. Thus,
there is great need to understand and mitigate the effects of smoking
as it relates to the development and treatment of lung cancer.
Activating mutations in K-Ras have been identified in approx-
imately 25% of human lung adenocarcinomas that are primarily
associated with smoking [3–5]. In preclinical models, K-Ras
mutations are observed in over 90% of lung tumors induced by
the tobacco-specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-
1-butanone (NNK). Oncogenic K-Ras stimulates activation of the
Akt/mTOR pathway, which contributes to the development of lung
tumors [6,7]. The FDA-approved immunosuppressant, rapamycin,
as well as its analogues, are mTOR inhibitors, and this class of drugs
decreases K-Ras induced lung tumorigenesis in mice. We recently
reported that rapamycin, when administered to achieve physiolog-
ically relevant trough levels, reduced NNK-induced lung tumori-
genesis in A/J mice by 90% [8]. These results are consistent with
studies of transgenic models of prostate, breast and lung cancer,
where treatment with rapamycin or rapamycin analogues prevented
or reversed premalignant lesions [7,9,10]. Thus, early steps of
tumorigenesis in many mouse models of cancer are reliant on
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preventive approach, little is known about the mechanisms
underlying its efficacy.
Activation of K-Ras in the mouse lung generates an
inflammatory process. In A/J mice, inflammation is highly
associated with susceptibility to NNK-induced lung tumorigenesis.
In mice genetically engineered to express mutant K-Ras, mTOR
inhibition has been shown to reduce inflammatory processes in the
lung [7]. The immunosuppressive properties of mTOR inhibitors,
coupled with their efficacy for tumor prevention in mouse models,
suggested that modulation of the immune system is important for
mutant K-Ras mediated lung tumorigenesis. Regulatory T cells
(Treg) suppress autoreactive T cells, and thus prevent autoimmu-
nity [11]. Treg are a subset of CD4+ T cells and express the
transcription factor, Foxp3 [12]. Preclinical studies suggest that
Treg may play an important role in limiting the development of an
effective immune response against cancer [13]. Tumor-associated
Treg have been observed in lymphomas and human cancers of the
lung, ovary, breast, prostate, and colon [14,15]. In lung cancer,
Treg are increased in tumor tissue relative to surrounding normal
lung tissue and are associated with an increased risk of recurrence
[15]. Treg also regulate the ability of inhibitors of cyclooxygenase-
II to decrease lung tumorigenesis in xenograft and viral models of
lung tumorigenesis [16]. Because rapamycin can alter T cell
function and prevent the development of NNK-induced lung
tumors that are associated with K-Ras mutations, we hypothesized
that modulation of immune function might be an important
determinant of lung tumorigenesis. Our studies show that
rapamycin unexpectedly counteracts an increase in lung-associat-
ed Treg by NNK that precedes the detection of tumors. Depletion
of Treg using an antibody or genetic deletion also greatly
diminished lung tumorigenesis in other K-Ras driven mouse
models, suggesting a new strategy that might have utility for lung
cancers characterized by mutations in K-Ras.
Methods
Mice
A/J and Foxp3
sf/+ mice were obtained from Jackson Labora-
tories (Bar Harbor, ME) at 5 weeks of age and housed according to
the guidelines of the Animal Care and Use Committee of the
National Institutes of Health (NIH). K-Ras
LA2 mice were obtained
from the Mouse Models of Human Cancer Consortium and
housed according to the same guidelines. For the NNK study, 10
6-week old female A/J mice per group were given three 100 mg/
kg doses of NNK or saline (EaglePicher Phamaceuticals, Lenexa,
KS) as previously described [8]. IO33 cells were a generous gift of
Dr. Steven Belinsky (U. of New Mexico Cancer Center) and
1610
5 cells were injected via tail vein in 100 ml of normal saline
into 6-week old A/J females. Genetically modified mice were
genotyped by polymerase chain reaction as described previously
according to published protocols (http://mouse.ncifcrf.gov for
Kras
LA2 and JAX.org for Scurfy).
Rapamycin was obtained from LC Laboratories (Woburn, MA)
and injected at 1.5 mg/kg every other day following a 4.5 mg/kg
loading dose as previously described. For IO33 studies, mice were
treated for 2 weeks with rapamycin following the same dosing
schedule, or anti-CD25 antibody (Harlan Biosciences) or rat non-
immune IgG1 (Sigma) (0.5 mg 26/wk for week 1, followed by
0.5 mg/wk) that was begun one week prior to IO33 injection.
Enumeration of Splenic Cells
Cells were analyzed by three-color flow cytometry on a
FACSCalibur (BD Biosciences, San Jose, CA) instrument using
CellQuest software (BD Biosciences). Intracellular flow cytometry
using the APC anti-mouse/rat Foxp3 staining set from eBioscience
(San Diego, CA) was used according to manufacturers instructions.
Five to ten thousand live events were acquired for analysis, with
propidium iodide exclusion of dead cells.
Immunohistochemical and immunoblotting analyses
Detection of Foxp3 and CD3 cells by IHC was performed using
the FJK-16s anti-mouse/rat Foxp3 antibody from eBioscience
(San Diego, CA) and the anti-human CD3 antibody from DAKO
(Carpinteria, CA) using the manufacturer’s instructions. IHC
analysis of lung tissues from mice treated with rat IgG or anti-
CD25 antibodies was performed using a biotinylated anti-mouse/
rat Foxp3 antibody (eBioscience, clone FJK-16s). Numbers of lung
infiltrating cells were assessed on a single lung section from 5
mice/group. Immunoblotting for Foxp3 expression in human and
murine lung cell lines was performed using the eBio7979 anti-
mouse/human Foxp3 antibody from eBiosciences (San Diego,
CA) using the manufacturer’s recommendation.
Statistical Analyses
Comparisons between two groups were performed using a
Wilcoxon rank sum test. A Jonckheere-Terpstra trend test was
used to determine the association of Foxp3 expressing cells with
the number of tumors. All p-values are two-tailed and have not
been adjusted for multiple comparisons.
Results
Tobacco carcinogen exposure increases lung associated
Foxp3+ cells
A/J mice were treated with NNK, and immune cell number
and function were characterized in splenocytes and lung tissues.
One week after completion of three weekly doses of NNK, NNK
decreased splenocyte number but not function (data not
shown), and caused a 21% relative increase in splenic
CD4+CD25+Foxp3+ regulatory T cells (Fig. 1a, left panel).
Because regulatory T cells are associated with tumor tolerance, we
hypothesized that a similar increase in Foxp3+ regulatory T cells
in lung tissues may be associated with tobacco carcinogen-induced
tumorigenesis. Immunohistochemistry was used to assess Foxp3+
cells and CD3+ cells in lung tissues from NNK-treated mice.
One week after administration of either a single dose or three
doses of NNK (and prior to the development of tumors), the
fraction of lung associated Foxp3+/CD3+ cells increased 2- and
4 - f o l d ,r e s p e c t i v e l y( F i g .1 a ,r i g h tp a n e l ) .L u n g - a s s o c i a t e d
Foxp3+ cells correlated with NNK-induced lung tumorigenesis,
because 16 weeks after administration of NNK, there was a trend
between the number of tumors per lung and the number of
Foxp3+ cells in surrounding lung tissues (Fig. 1b). Induction of
lung tumors and tumor-associated Foxp3+ cells by NNK was
also dose-dependent. A single dose of NNK induced twice as
many tumors and Foxp3+ cells as spontaneous tumors (data not
shown). Mice that received three doses of NNK had nearly three
t i m e sa sm a n yt u m o r sa n di n f i l t r a t i n gF o x p 3 + c e l l sa sm i c et h a t
received one dose of NNK (Fig. 1c-d). Because expression of
Foxp3 has been reported in lung epithelial cells and some tumor
cell lines [17–19], we co-stained lung tissues or lymph nodes for
Foxp3 and CD3 expression, and confirmed that expression of
Foxp3 was observed in CD3+ cells but not epithelial cells (Fig.
S1a–e). In addition, Foxp3 protein was not expressed in human
lung cancer cell lines or cell lines derived from murine lung
tumors (Fig. S1f).
Treg, K-Ras, and Lung Cancer
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decrease lung tumorigenesis
Rapamycin inhibits lung tumorigenesis more effectively when it
is administered prior to the detection of tumors. To assess whether
this observation is related to lung-associated Foxp3+ cells, A/J
mice were treated with NNK, and lungs and spleens were
harvested at various time points after administration of rapamycin
or vehicle. Consistent with earlier studies, rapamycin markedly
decreased the size and multiplicity of NNK-induced lung tumors
(Fig. 2a). mTOR was inhibited in tumor cells and normal airway
epithelium (Fig. S2a), and steady state rapamycin levels were
constant throughout the study. Rapamycin rapidly reversed the
induction of lung-associated Foxp3+ cells by NNK, and
maintained depletion of Foxp3+ cells throughout the study
(Fig. 2c–d), even though splenic CD4+CD25+Foxp3+ cells were
increased at 12 wk by rapamycin (Fig. S2b), consistent with
previous results [20]. The depletion of lung-associated Foxp3+
cells preceded tumor development because the number of Foxp3-
expressing cells was decreased by 84% after 1 week of treatment
(when tumors were not visible). Although rapamycin also reduced
the overall number of CD3+ T cells (data not shown), the Foxp3+/
CD3+ ratio was depleted to levels observed in non-NNK exposed
mice (Fig. 2c). Tumors that did arise in the presence of rapamycin
had fewer infiltrating Foxp3+ cells than controls, even after
accounting for their smaller size (Fig. 2d). Thus, NNK and
rapamycin reciprocally regulate Foxp3+ cells in lung tissues prior
to tumor development, suggesting that lung-associated Foxp3+
cells contribute to tumorigenesis.
To test this hypothesis, an antibody against CD25 that can
deplete Treg was administered to A/J mice after exposure to
NNK, and lung tumorigenesis was assessed after 16 wk (data not
shown). Although splenic CD25+ cells were rapidly decreased by
90% and maintained for the length of the study, lung associated
Foxp3+ cells were only decreased transiently. After 16 wk, there
was no inhibition of lung tumorigenesis and no decrease in lung
associated Foxp3+ cells. Because long-term depletion of lung-
associated Foxp3+ cells by anti-CD25 antibodies was not
achievable, we developed a short-term assay, and performed a
series of studies using syngeneic lung adenocarcinoma cell lines
Figure 1. NNK increases Foxp3+ cells. (a) Assessment of Foxp3+ cells in splenic and lung tissues. One week after NNK exposure, Foxp3+ T cell
subsets were assessed in spleens (left) as a fraction of total CD4+ splenocytes and in lungs (right) as a fraction of total CD3+ cells. (b) Correlation of
number of NNK-induced lung tumors with number of Foxp3+ cells in surrounding lung tissues. Tumors were counted in mice 16 wk after NNK
administration, and scoring for Foxp3+ cells was performed using IHC. A trend for the number of Foxp3+ cells in surrounding normal lung with the
number of tumors per lung is shown. (c–d) Dose-dependent induction of lung tumors (c) and Foxp3+ cells (d) by NNK. For (a, b, and d), boxes
indicate interquartile range, lines indicate median, and whiskers indicate minimal and maximal values. For (a and c), each point represents a mouse
and the line represents the median. A high-powered field (HPF) indicates a field under 1006magnification.
doi:10.1371/journal.pone.0005061.g001
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the other lung adenocarcinoma cell lines tested, IO33 cells were
most resistant to inhibition of proliferation by rapamycin in vitro
(Fig. S3a) despite inhibition of mTOR (Fig. S3b). When injected
via tail vein, IO33 cells rapidly formed highly invasive lung
adenocarcinomas in A/J mice (Fig. S3c). Treatment of IO33-
injected mice with rapamycin had no effect on tumorigenesis
(Fig. 3a) and did not affect the number of tumor-associated
Foxp3+ cells (Fig. 3b), despite inhibition of mTOR in normal
bronchial epithelium and IO33 tumors (Fig. S3d). Varying the
sequence of rapamycin administration and cell injection did not
increase responsiveness of the IO33 cells (data not shown). Because
the anti-CD25 antibody decreased lung-associated Foxp3+ cells
with short term-treatment, inoculation studies with IO33 cells
were repeated, and A/J mice were treated with the anti-CD25
antibody prior to injection of IO33 cells. Treatment with anti-
CD25 antibody decreased splenic Foxp3+CD25+ cells by 95%
(Fig. 3c, left panel), decreased lung-associated Foxp3+ cells by 65%
(Fig. 3c, right panel) and decreased the multiplicity of IO33
adenocarcinomas by 80% (Fig. 3d). These results are similar to the
results observed with rapamycin in the studies using NNK.
Genetic ablation of Foxp3+ cells decreases K-Ras
mediated tumorigenesis
A comparison of tumor-associated Treg in the KRas
LA2 model of
lung cancer was performed to assess whether the induction of
Foxp3+ cells was a general feature of K-Ras driven lung
tumorigenesis or specific for NNK-induced tumors. K-Ras
LA2 mice
develop early-onset lung adenocarcinomas [22]. Foxp3+ and CD3+
cells were detected in each tumor type, and the overall number of
Foxp3+ and CD3+ cells was lower in K-Ras
LA2 mice than in mice
treated with NNK (Fig. 4a). However,thefraction ofFoxp3+/CD3+
cells was not statistically different between NNK-induced tumors
and tumors from KRas
LA2 mice (Fig. 4b). To confirm the role of
Figure 2. Rapamycin prevents NNK-induced tumorigenesis and depletes lung-associated Foxp3+ cells in NNK-treated mice. (a)
Tumor multiplicity (left) and tumor size (right) after 12 wk of rapamycin or vehicle. (b) Representative staining for Foxp3+ cells in tumors (TU) and
normal airway epithelium (NL). (c) The fraction of Foxp3+/total CD3+ cells in normal lung tissues from saline or NNK-exposed mice treated with
rapamycin or vehicle for 1, 4 or 12 weeks was calculated after IHC was performed. The red and white dots at week 0 indicate the percentages of
Foxp3+/CD3+ cells in the lungs of A/J mice prior to and after NNK administration, respectively. (d) The number of Foxp3+ cells in tumors arising 16
weeks after NNK exposure in the presence or absence of rapamycin was determined using IHC. For (a, c, and d), boxes indicate interquartile range,
lines indicate median, and whiskers indicate minimal and maximal values. A high-powered field (HPF) indicates a field under 1006magnification.
doi:10.1371/journal.pone.0005061.g002
Treg, K-Ras, and Lung Cancer
PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e5061Foxp3+ cells in this system, K-Ras
LA2 mice were crossed to scurfy
mice. Scurfy mice bear a loss-of-function mutation in the Foxp3
transcription factor (Foxp3
sf/+). Hemizygous males lack Foxp3+ cells
and develop lethal autoimmunitythatphenocopies the human IPEX
syndrome [23,24]. Because Foxp3 is x-linked, lung tumorigenesis was
assessed in 3-week-old K-Ras
LA2Foxp3
sf/Y males. Scurfy males were
distinguishable from their wildtype littermates by their small size and
scaly skin, but were not moribund at the time of sacrifice.
Lymphocytic infiltrates were observed in lungs from scurfy males,
although the severity varied widely (data not shown). Compared to
K-Ras
LA2Foxp3
+/Y males, K-Ras
LA2Foxp3
sf/Y males developed 75%
fewer tumors (Fig. 4c). These data confirm in a third model system
that depletion of Foxp3+ cells inhibits K-Ras driven lung
tumorigenesis.
Discussion
Using carcinogen, allograft and transgenic models of lung
cancer driven by K-Ras, we have shown that Foxp3+ cells are
essential for lung tumorigenesis. The tissue specific induction of
Foxp3+ cells in lung tissues prior to tumor development suggests
that NNK-induced Foxp3+ T cells provide a permissive
environment for the development of K-Ras-driven lung tumors.
Such an environment may also be important for the development
of lung metastasis, because smoking can double the metastatic
burden in lungs in preclinical models [25].
A common feature linking smoking induced K-Ras mutations
in human lung cancer and preclinical models driven by tobacco
carcinogens that cause K-Ras mutations is inflammation. In both
cases, the presence of Foxp3+ cells is likely important for limiting
the extent of inflammation and tissue damage, albeit at a
potential cost of promoting tumorigenesis. Smoking causes
chronic obstructive pulmonary disease (COPD), which is an
independent risk factor for lung cancer [26]. Bronchoalveolar
lavage (BAL) fluid from patients with COPD or smokers contains
increased Treg compared to BAL fluid from healthy never
smokers [27]. Similarly, smoking is also associated with
squamous cell carcinoma (SCC) of the oral cavity, and increased
Figure 3. Depletion of Foxp3+ cells using an anti-CD25 antibody decreases the ability of rapamycin-resistant lung adenocarcinoma
cells to form tumors. (a–b) Effect of rapamycin on IO33 tumor multiplicity (a) or tumor-associated percent of Foxp3+/CD3+ cells (b). (c) Effect of rat
IgG or anti-CD25 antibodies on the number of splenic Foxp3+CD25+/CD4+ cells (left) and IO33 tumor-associated %Foxp3+/CD3+ cells (right). (d)
Effect of anti-CD25 antibody or rat IgG on IO33 lung tumor multiplicity. For (a) and (d), boxes indicate interquartile range, lines indicate median, and
whiskers indicate minimal and maximal values. For (b–c), each point represents a mouse and the line represents the median. n.s., not significant.
doi:10.1371/journal.pone.0005061.g003
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cancerous epithelial tissues [28]. NNK, the most prevalent
tobacco carcinogen, alters many components of inflammation,
including cytokine expression and cellular immunity, and the
susceptibility of different mouse strains to NNK-induced lung
tumorigenesis has been linked to differences in lung immunity
[22]. One important alteration caused by NNK is induction of
cyclooxygenase II (COX-2) activity. Inhibitors of COX-2 can
decrease NNK-induced lung tumorigenesis [29], and Sharma et
al. have shown that the ability of COX-2 inhibitors to decrease
lung tumorigenesis (in models not related to tobacco) is
dependent upon decreasing Foxp3+ cells [16].
Inflammation is also associated with lung tumorigenesis in
transgenic mice that express mutant K-Ras in lung tissues. Our
studies showed that the ratio of Foxp3+/CD3+ cells was not
statistically different between the NNK model and the K-Ras
LA2
model, but the total numbers of each cell type was increased in
the tobacco carcinogen model. Eliminating Foxp3+ cells by
crossing K-Ras
LA2 mice to scurfy mice nonetheless decreased
lung tumorigenesis, which shows that even though fewer tumor
infiltrating lymphocytes were induced in the K-Ras
LA2 model,
Foxp3+ cells still played a critical role. The increased
inflammatory response in lungs from scurfy mice that occurred
as a result of loss of Foxp3+ cells may have decreased tumor
growth through elimination of nascent tumors. Wislez et al.
previously showed an important role for alveolar macrophages in
mediating inhibition of tumor growth by high doses of a
rapamycin analogue in a transgenic model of lung cancer similar
to K-Ras
LA2 (K-Ras
LA1). However, alterations in Foxp3+ cells
were not reported in this study. Because activated macrophages
and tumor cells can recruit Foxp3+ cells [30,31], it is possible
that the role attributed to alveolar macrophages was mediated
through activation of Foxp3+ cells. Together, these studies show
that Foxp3+ cells provide a critical link between inflammation
Figure 4. Genetically engineered mice that lack Foxp3+ cells develop fewer K-Ras driven lung tumors. (a) Representative IHC of tumor-
associated Foxp3+ and CD3+ cells in tobacco-carcinogen (NNK) and K-ras
LA2 transgenic mouse models of lung tumorigenesis. (b) Quantification of
IHC analysis in (a) for tumor-associated percent of Foxp3+/CD3+ cells. Each point represents a mouse and the line represents the median; n.s., not
significant. (c) Tumor multiplicity in K-RAS
LA2/wt/Foxp3
2/Y or K-RAS
LA2/wt/Foxp3
+/Y offspring. Boxes indicate interquartile range, lines indicate
median, and whiskers indicate minimal and maximal values.
doi:10.1371/journal.pone.0005061.g004
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mutant K-Ras, and highlight the possibility that careful titration
of lung- associated Foxp3+ cells might allow effective anti-tumor
immunity without tissue damage from unabated inflammation.
Although these studies provide rationale to target Foxp3+ cells
for the prevention or treatment of K-Ras-driven lung tumors, the
responsiveness of Foxp3+ cells may depend on the agent utilized
to target Foxp3+ cells and the transformation status of the cells
that bear K-Ras mutations. For example, rapamycin selectively
reduced the number of Foxp3+ cells induced by NNK in lung
tissues prior to tumor development, thereby providing a
reciprocal relationship with NNK, but had no effect when fully
transformed IO33 adenocarcinoma cells were injected. Similar
results were observed when rapamycin was administered after
NNK-induced lung tumors were allowed to develop in A/J mice
for 26 wk [8]. When administered from week 26 to week 32,
rapamycin decreased tumor size by 50% but did not affect tumor
multiplicity, and the number of tumor infiltrating Foxp3+ cells
was not decreased (data not shown). The clinical experience with
analogues of rapamycin that have been tested as cancer
therapeutics is consistent with these preclinical observations, in
that mTOR inhibitors only have modest activity as single agents
in patients with advanced lung cancer [32,33]. Taken together,
these data suggest that rapamycin, which is an FDA-approved
oral agent with a high therapeutic index, might be most effective
as a preventative strategy primarily for smokers with premalig-
nant lesions or carcinomas in situ that bear occult K-Ras
mutations.
Aggressive and invasive K-Ras-induced adenocarcinomas
(IO33 and K-Ras
LA2) remained sensitive to more direct targeting
of Foxp3+ cells through a neutralizing anti-CD25 antibody or
genetic deletion. This indicates that direct Treg cell depletion
strategies that are being evaluated clinically [34] could have
therapeutic value in more advanced stages of K-Ras driven lung
cancer. However, the fact that long-term administration of an
anti-CD25 antibody was effective in splenocytes but not in lung
tissues suggests that there may be tissue specificity for the ability
of antibodies to deplete Foxp3+ cells and/or that compensatory
mechanisms such as increases in CD25-/Foxp3+ cells occur with
long-term use. Therefore, other therapeutic approaches may
need to be developed to selectively deplete Foxp3+ cells in
advanced K-Ras driven lung cancers. The development of
multiple therapies that deplete Foxp3+ cells at different stages of
K-Ras induced tumorigenesis might eventually provide new
options for lung cancer treatment and prevention.
Supporting Information
Figure S1 Foxp3 is expressed in CD3+ lymphocytes, but is not
detectable in murine lung epithelium or lung epithelium-derived
cultured cell lines. (a–e) Representative immunohistochemical
co-staining of Foxp3 and CD3 in cells from NNK-induced A/J
mice lung adenomas (a–c) and lung-associated lymph nodes (d–
e). Foxp3 is blue/gray and CD3 is brown. (f) Immunoblotting
analysis for Foxp3 expression in human and murine lung cell
lines. Cells were treated with 100 nM rapamycin or vehicle for
24 hr to confirm lack of expression of Foxp3 in these cell lines
and lack of inhibition of Foxp3 expression by rapamycin. H157
and A549 are human lung adenocarcinoma cell lines; HBEC are
human bronchial epithelial cell lines immortalized with CDK4
and h-TERT with or without K-Ras mutations (KTR and KTC,
respectively); hPBMCs are human peripheral blood mononucle-
ar cells that were used as a positive control; IO33, CL13, CL25,
and CL30 are lung adenocarcinoma cell lines derived from
NNK-induced tumors in A/J mice.
Found at: doi:10.1371/journal.pone.0005061.s001 (2.43 MB TIF)
Figure S2 Rapamycin inhibits mTOR in lung tissues and
increases the fraction of Foxp3+/CD4+ splenocytes. (a) Repre-
sentative IHC of phospho-S6 in normal lung (NL) and lung
tumors (TU) 16 hours after the last dose of rapamycin in A/J
mice. (b) During the tumorigenesis study, the effects of
rapamycin versus vehicle on percent of splenocytes that were
Foxp3+/CD4+ cells was assessed using FACS after 1, 4, and 12
weeks of treatment. The red and white dots at week 0 indicate
the basal percent of splenic Foxp3+/CD4+ cells prior to and
after NNK administration, respectively. Boxes indicate inter-
quartile range, lines indicate median, and whiskers indicate
minimal and maximal values.
Found at: doi:10.1371/journal.pone.0005061.s002 (1.21 MB TIF)
Figure S3 IO33 cells are resistant to growth inhibition by
rapamycin and form invasive lung tumors in A/J mice. (a) Dose-
dependent inhibition of proliferation of murine and human lung
cancer cell lines by rapamycin. In vitro, rapamycin only
modestly inhibits proliferation of IO33 cells relative to other
A/J-derived lung adenocarcinoma cell lines (CL30, CL25, and
CL13) and human lung cancer cells (H1155). (b) Rapamycin
inhibits mTOR in IO33 cells in vitro. mTOR inhibition was
evaluated by immunoblotting analysis of cells treated with
rapamycin for 2 h using antibodies specific for mTOR
substrates, phospho-S6 and total 4E-BP1. (c) Syngeneic IO33
cells form invasive lung tumors in A/J mice when injected via tail
vein. A representative whole mount of A/J lungs and heart 2 wk
after tail vein injection with 106 IO33 cells is shown. Note multi-
focal lung tumors and invasion into the ventricular wall. (d)
Rapamycin inhibits mTOR in vivo, as assessed by IHC analysis
of phospho-S6 in normal lung (NL) and IO33 lung tumors (TU)
in A/J mice.
Found at: doi:10.1371/journal.pone.0005061.s003 (3.21 MB TIF)
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